Thermo Fisher Scientific (NYSE:TMO) Shares Gap Up on Better-Than-Expected Earnings

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $526.46, but opened at $573.68. Thermo Fisher Scientific shares last traded at $573.9670, with a volume of 1,505,888 shares traded.

The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific’s revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher beat Q2 expectations, posting $6.03 adjusted EPS versus the $5.71 consensus and $11.99 billion in revenue versus $11.71 billion expected, helped by stronger customer activity across end markets and continued organic growth. Article Title
• Positive Sentiment: The company also raised FY2026 guidance, now calling for EPS of $24.93 to $25.33 and revenue of $47.4 billion to $48.1 billion, both above Wall Street estimates, which suggests management is seeing a healthier operating backdrop.
• Positive Sentiment: Earlier reports noted shares rose in premarket trading after the earnings beat, reflecting investor optimism that demand is improving across Thermo Fisher’s life sciences, diagnostics, and lab equipment businesses. Article Title
• Neutral Sentiment: ImmuPharma selected Thermo Fisher’s Patheon unit to manufacture its Kapiglucagon diabetes candidate, a modest business-development win that adds some incremental contract manufacturing exposure but is unlikely to move the stock on its own. Article Title

Wall Street Analysts Forecast Growth

TMO has been the subject of several research reports. Barclays decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective on the stock. Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. Finally, Morgan Stanley reissued an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $602.14.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several institutional investors and hedge funds have recently modified their holdings of TMO. Vanguard Group Inc. increased its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after buying an additional 288,296 shares during the last quarter. J. Stern & Co. LLP boosted its stake in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares in the last quarter. State Street Corp raised its stake in shares of Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after acquiring an additional 229,630 shares in the last quarter. Capital World Investors lifted its holdings in Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after purchasing an additional 718,669 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Thermo Fisher Scientific by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after purchasing an additional 26,425 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

The firm has a fifty day simple moving average of $488.92 and a 200 day simple moving average of $513.21. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The company has a market cap of $213.19 billion, a price-to-earnings ratio of 31.54, a P/E/G ratio of 2.32 and a beta of 0.87.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.